Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma

The diagnosis of smoldering multiple myeloma (SMM) includes patients with a heterogeneous risk of progression to active multiple myeloma (MM): some patients will never progress, whereas others will have a high risk of progression within the first 2 years. Therefore, it is important to improve risk a...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2016-10, Vol.30 (10), p.2026-2031
Main Authors: González-Calle, V, Dávila, J, Escalante, F, de Coca, A G, Aguilera, C, López, R, Bárez, A, Alonso, J M, Hernández, R, Hernández, J M, de la Fuente, P, Puig, N, Ocio, E M, Gutiérrez, N C, García-Sanz, R, Mateos, M V
Format: Article
Language:English
Subjects:
692/699/1541/1990/804
82/1
82/29
Adult
Aged
Aged, 80 and over
Analysis
Bence Jones Protein - urine
Biological markers
Biomarkers, Tumor - urine
Cancer Research
Capillary electrophoresis
Care and treatment
Confidence intervals
Critical Care Medicine
Development and progression
Diagnosis
Disease Progression
Female
Hematology
Humans
Identification and classification
Independent variables
Intensive
Internal Medicine
Leukemia
Magnetic resonance imaging
Male
Medicine
Medicine & Public Health
Middle Aged
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - urine
Oncology
original-article
Physiological aspects
Plasma
Proteins
Proteinuria
Retrospective Studies
Risk Assessment
Risk groups
Smoldering
Subgroups
Time Factors
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The diagnosis of smoldering multiple myeloma (SMM) includes patients with a heterogeneous risk of progression to active multiple myeloma (MM): some patients will never progress, whereas others will have a high risk of progression within the first 2 years. Therefore, it is important to improve risk assessment at diagnosis. We conducted a retrospective study in a large cohort of SMM patients, in order to investigate the role of Bence Jones (BJ) proteinuria at diagnosis in the progression to active MM. We found that SMM patients presenting with BJ proteinuria had a significantly shorter median time to progression (TTP) to MM compared with patients without BJ proteinuria (22 vs 88 months, respectively; hazard ratio=2.3, 95% confidence interval=1.4–3.9, P= 0.002). We also identified risk subgroups based on the amount of BJ proteinuria: ⩾500 mg/24 h,
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2016.123